Uro­Gen nabs $120M to sup­port po­ten­tial 2024 NDA fil­ing, launch of blad­der can­cer chemo gel

Uro­Gen Phar­ma’s hy­dro­gel for­mu­la­tion of a decades-old can­cer drug met the pri­ma­ry end­points in two Phase III tri­als of a sub­set of blad­der can­cer, the biotech said Thurs­day morn­ing.

The da­ta in­trigued in­vestors enough to back a $120 mil­lion pri­vate place­ment that will help bankroll a po­ten­tial NDA fil­ing in the sec­ond half of next year, as well as a po­ten­tial launch of the drug, CEO and pres­i­dent Liz Bar­rett told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER